Compare DexCom, Inc. (DXCM) vs Upstart Holdings Inc (UPST) Price & Performance

DXCM trades at $77.31, up 4.3% on the day, with a bullish technical outlook as it approaches resistance near $78. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.56 surpassing expectations of $0.47. Revenue growth accelerated to $4.66 billion in 2025, while net income margin expanded to 17.93%. Recent regulatory approvals, including Health Canada authorization for the G7 15-day CGM, support continued international expansion.

The stock offers growth potential with analyst consensus price target of $84.33, though high valuation multiples (P/E 31.21) and competition in the CGM market present risks. Expansion into non-insulin Type 2 diabetes and pediatric markets could drive future revenue, but commercial uptake remains unproven. Institutional sentiment remains strongly bullish with 80% buy ratings.

Upstart Holdings (UPST) trades at $30.86, down 2.71% today, with a bearish technical signal from moving averages but oversold RSI conditions. The company reported a return to profitability in 2025 with $1.02B revenue and $53.60M net income, though recent Q1 2026 earnings missed expectations. Analyst sentiment is divided with a $42.00 consensus price target, while cash flow trends show improved but still negative operational cash generation.

UPST presents a high-risk, high-reward opportunity with strong AI lending growth potential but faces execution risks and margin pressure. The stock's current valuation at 77x P/E demands flawless execution of expansion into auto and home loans. Near-term performance hinges on Q2 2026 results due August 4, 2026, with investors watching for sustained profitability and funding stability.